New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
05:55 EDTABBV, ABBV, ABBV, MRK, MRK, MRK, PFE, PFE, PFE, RHHBY, RHHBY, RHHBY, SYK, SYK, SYK, TEVA, TEVA, TEVA, COV, COV, COV, CERN, CERN, CERN, BAYRY, BAYRY, BAYRY, ABT, ABT, ABT, LPNT, LPNT, LPNTAmerican Congress of Obstetrics and Gynecology to hold annual meeting
61st Annual Meeting to be held in New Orleans on May 4-8.
News For ABBV;ABT;BAYRY;CERN;COV;TEVA;SYK;RHHBY;PFE;MRK;LPNT From The Last 14 Days
Check below for free stories on ABBV;ABT;BAYRY;CERN;COV;TEVA;SYK;RHHBY;PFE;MRK;LPNT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 9, 2014
11:43 EDTMRK, ABT, ABBVGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTMRKEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTBAYRY, MRKReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
16:10 EDTRHHBYProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.
11:03 EDTMRK, PFE, RHHBYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
08:46 EDTTEVATeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
07:26 EDTCOVElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
17:28 EDTPFEPfizer sell-off unwarranted, Barron's says
Subscribe for More Information
16:28 EDTPFEOn The Fly: Closing Wrap
Subscribe for More Information
14:09 EDTTEVASun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information
12:15 EDTPFEOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTPFEPfizer trades near lows of the day, levels to watch
Subscribe for More Information
09:10 EDTPFEOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:09 EDTPFEConfusion on Pfizer Palbo could create buying opportunity, says BMO Capital
Subscribe for More Information
09:00 EDTPFEPfizer falls 2.8%
Pfizer is down 2.8%, or 90c, to $31.25
08:09 EDTMRKAlnylam's McSwiggen patent upheld in European opposition proceedings
Subscribe for More Information
07:27 EDTPFE, MRKAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
06:07 EDTRHHBYRoche acquires IQuum for $450M
Subscribe for More Information
April 6, 2014
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use